Although not approved for any viral infection, HSP90 inhibitors have long been touted as potential broad-spectrum antiviral agents, and like poliovirus and EV-A71 (5, 13), HSP90 inhibitors have significant antiviral activity against HAV in a murine model of infection. This evidence concerns the gene HSP90AA1 and infection.